Nashville, TN, USA, July 26, 2018 – IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces the market launch of SMARTSCAN at the 60th annual AAPM meeting.
SMARTSCAN is the first commissioning solution for linear accelerators and RTPS systems that guides the user through the whole process and automates repetitive tasks. As a result, beam data commissioning and accelerator QA is constantly executed with optimal quality, which is the foundation for the safe and accurate treatment of every patient. Next to quality beam data, SMARTSCAN inherently enables commissioning work to be completed efficiently in less time, allowing sooner clinical implementation of new equipment and therefore more patient throughput.
“We have been commissioning Linear Accelerators as a dedicated service line of our business for over ten years now utilizing the IBA dosimetry systems. This equates to well over 250 commissioning's making us routinely aware of the major challenges that radiation therapy centers face in bringing a new machine on-line. The staff physicist does not use a water phantom every day and there is a growing need of expertise especially with the complexity of the latest Linear Accelerator technologies” said Jonathan Rogers, MS DABR-Senior Physicist, Commissioning Services at Alyzen Medical Physics services. “We have intensively evaluated the new SMARTSCAN solution from IBA. SMARTSCAN will make a significant impact in the data acquisition efficiency and as well the quality of the data. Experienced users should be able to perform their data collection even faster and new or less experienced users will have a much shorter learning curve with confidence that the data is correct. SMARTSCAN is something us physicist have needed for many years.”
SMARTSCAN overcomes the heavy and tedious user involvement needed with traditional systems, which often lead to lengthy commissioning times and compromised quality. SMARTSCAN guides the user along the entire commissioning process – from system setup to the actual scanning of the entire data set. SMARTSCAN plans precisely what needs to be done, optimizes each step of the workflow, automates repetitive tasks, and continuously keeps track of the accuracy of the process. To ensure optimal beam data quality, SMARTSCAN checks every single scan during the process; suspicious measurements are flagged immediately to eliminate waste data and to save time.
“Commissioning is a very intensive effort for medical physicists that not only requires in-depth experience but a lot of time to measure and analyze about 1,000 beam scans” saidJean-Marc Bothy, President of IBA Dosimetry GmbH. “As the inventors of computerized water phantoms, and with over 40 years of experience, we designed a brand new solution. SMARTSCAN defines state of the art in beam commissioning and annual Linac QA.”
To find out more please visit iba-dosimetry.com
SMARTSCAN is the efficient and precise solution to operate Linac and RTPS beam commissioning and annual QA. It guides the user efficiently through the whole workflow and automates repetitive tasks. SMARTSCAN is designed to deliver optimal beam data quality with highest standards in the shortest time – constantly. This is the optimal basis for accurate patient treatments and fast implementation of new Linac and RTPS equipment and annual QA.
SMARTSCAN is a trademark of IBA.
About IBA Dosimetry
IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.
Find more information at iba-dosimetry.com
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at iba-worldwide.com
Director Global Marketing, IBA Dosimetry, email@example.com